← Back to Portfolio

SFJ Pharmaceuticals IX

SFJ Pharmaceuticals IX formed a deal with Baxalta focused on obtaining US and European approval for an undisclosed biosimilar product. However, following Shire Pharmaceutical’s acquisition of Baxalta, Shire terminated the agreement for strategic reasons and SFJ IX received an agreed-upon multiple.

LocationPleasanton, California
CEORobert DeBenedetto
PartnerKen Haas
Websitewww.sfj-pharma.com